Cargando…

Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction

BACKGROUND: As of 2009, anticoagulation with citrate was standard practice in continuous renal replacement therapy (CRRT) for critically ill patients at the University Medical Centre of Saarland, Germany. Partial hepatic metabolism of citrate means accumulation may occur during CRRT in critically il...

Descripción completa

Detalles Bibliográficos
Autores principales: Klingele, Matthias, Stadler, Theresa, Fliser, Danilo, Speer, Timo, Groesdonk, Heinrich V., Raddatz, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707786/
https://www.ncbi.nlm.nih.gov/pubmed/29187232
http://dx.doi.org/10.1186/s13054-017-1870-3
_version_ 1783282509194199040
author Klingele, Matthias
Stadler, Theresa
Fliser, Danilo
Speer, Timo
Groesdonk, Heinrich V.
Raddatz, Alexander
author_facet Klingele, Matthias
Stadler, Theresa
Fliser, Danilo
Speer, Timo
Groesdonk, Heinrich V.
Raddatz, Alexander
author_sort Klingele, Matthias
collection PubMed
description BACKGROUND: As of 2009, anticoagulation with citrate was standard practice in continuous renal replacement therapy (CRRT) for critically ill patients at the University Medical Centre of Saarland, Germany. Partial hepatic metabolism of citrate means accumulation may occur during CRRT in critically ill patients with impaired liver function. The aim of this study was to evaluate the actual influence of hepatic function on citrate-associated complications during long-term CRRT. METHODS: In a retrospective study conducted between January 2009 and November 2012, all cases of dialysis therapy performed in the interdisciplinary surgical intensive care unit were analysed. Inclusion criteria were CRRT and regional anticoagulation with citrate, pronounced liver dysfunction, and pathologically reduced indocyanine green plasma disappearance rate (ICG-PDR). RESULTS: A total of 1339 CRRTs were performed in 69 critically ill patients with liver failure. At admission, the mean Model for End-stage Liver Disease score was 19.2, and the mean ICG-PDR was 9.8%. Eight patients were treated with liver replacement therapy, and 30 underwent transplants. The mortality rate was 40%. The mean duration of dialysis was 19.4 days, and the circuit patency was 62.2 h. Accumulation of citrate was detected indirectly by total serum calcium/ionised serum calcium (tCa/iCa) ratio > 2.4. This was noted in 16 patients (23.2%). Dialysis had not to be discontinued for metabolic disorder or accumulation of citrate in any case. In 26% of cases, metabolic alkalosis occurred with pH > 7.5. Interestingly, no correlation between citrate accumulation and liver function parameters was detected. Moreover, most standard laboratory liver function parameters showed poor predictive capabilities for accumulation of citrate. CONCLUSIONS: Our findings indicate that extra-hepatic metabolism of citrate seems to exist, avoiding in most cases citrate accumulation in critically ill patients despite impaired liver function. Because the citric acid cycle is oxygen-dependent, disturbed microcirculation would result in inadequate citrate metabolism. Raising the tCa/iCa ratio would therefore be an indicator of severity of illness and mortality rather than of liver failure. However, further studies are warranted for confirmation.
format Online
Article
Text
id pubmed-5707786
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57077862017-12-06 Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction Klingele, Matthias Stadler, Theresa Fliser, Danilo Speer, Timo Groesdonk, Heinrich V. Raddatz, Alexander Crit Care Research BACKGROUND: As of 2009, anticoagulation with citrate was standard practice in continuous renal replacement therapy (CRRT) for critically ill patients at the University Medical Centre of Saarland, Germany. Partial hepatic metabolism of citrate means accumulation may occur during CRRT in critically ill patients with impaired liver function. The aim of this study was to evaluate the actual influence of hepatic function on citrate-associated complications during long-term CRRT. METHODS: In a retrospective study conducted between January 2009 and November 2012, all cases of dialysis therapy performed in the interdisciplinary surgical intensive care unit were analysed. Inclusion criteria were CRRT and regional anticoagulation with citrate, pronounced liver dysfunction, and pathologically reduced indocyanine green plasma disappearance rate (ICG-PDR). RESULTS: A total of 1339 CRRTs were performed in 69 critically ill patients with liver failure. At admission, the mean Model for End-stage Liver Disease score was 19.2, and the mean ICG-PDR was 9.8%. Eight patients were treated with liver replacement therapy, and 30 underwent transplants. The mortality rate was 40%. The mean duration of dialysis was 19.4 days, and the circuit patency was 62.2 h. Accumulation of citrate was detected indirectly by total serum calcium/ionised serum calcium (tCa/iCa) ratio > 2.4. This was noted in 16 patients (23.2%). Dialysis had not to be discontinued for metabolic disorder or accumulation of citrate in any case. In 26% of cases, metabolic alkalosis occurred with pH > 7.5. Interestingly, no correlation between citrate accumulation and liver function parameters was detected. Moreover, most standard laboratory liver function parameters showed poor predictive capabilities for accumulation of citrate. CONCLUSIONS: Our findings indicate that extra-hepatic metabolism of citrate seems to exist, avoiding in most cases citrate accumulation in critically ill patients despite impaired liver function. Because the citric acid cycle is oxygen-dependent, disturbed microcirculation would result in inadequate citrate metabolism. Raising the tCa/iCa ratio would therefore be an indicator of severity of illness and mortality rather than of liver failure. However, further studies are warranted for confirmation. BioMed Central 2017-11-29 /pmc/articles/PMC5707786/ /pubmed/29187232 http://dx.doi.org/10.1186/s13054-017-1870-3 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Klingele, Matthias
Stadler, Theresa
Fliser, Danilo
Speer, Timo
Groesdonk, Heinrich V.
Raddatz, Alexander
Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction
title Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction
title_full Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction
title_fullStr Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction
title_full_unstemmed Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction
title_short Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction
title_sort long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707786/
https://www.ncbi.nlm.nih.gov/pubmed/29187232
http://dx.doi.org/10.1186/s13054-017-1870-3
work_keys_str_mv AT klingelematthias longtermcontinuousrenalreplacementtherapyandanticoagulationwithcitrateincriticallyillpatientswithsevereliverdysfunction
AT stadlertheresa longtermcontinuousrenalreplacementtherapyandanticoagulationwithcitrateincriticallyillpatientswithsevereliverdysfunction
AT fliserdanilo longtermcontinuousrenalreplacementtherapyandanticoagulationwithcitrateincriticallyillpatientswithsevereliverdysfunction
AT speertimo longtermcontinuousrenalreplacementtherapyandanticoagulationwithcitrateincriticallyillpatientswithsevereliverdysfunction
AT groesdonkheinrichv longtermcontinuousrenalreplacementtherapyandanticoagulationwithcitrateincriticallyillpatientswithsevereliverdysfunction
AT raddatzalexander longtermcontinuousrenalreplacementtherapyandanticoagulationwithcitrateincriticallyillpatientswithsevereliverdysfunction